Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.

Autor:	Tanaka H; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan., Enokida T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Okano S; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Fujisawa T; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Tanaka N; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Takeshita N; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan., Onaga R; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Hoshi Y; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan., Wada A; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Sato M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Ueda Y; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan., Tahara M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Nov 21; Vol. 13, pp. 1221352. Date of Electronic Publication: 2023 Nov 21 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1221352
Abstrakt:	Background: Immune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects' prognosis. Methods: We retrospectively reviewed 59 patients with R/M SCCHN treated with paclitaxel+cetuximab (PE)-based chemotherapy (PCE, paclitaxel+carboplatin+cetuximab; or PTX+Cmab, paclitaxel+cetuximab) following disease progression after either pembrolizumab or nivolumab monotherapy. Results: Of 59 patients, 15 were treated with pembrolizumab, with an ORR of 13.3%, and the remaining 44 with nivolumab, with an ORR of 11.4%. All patients in the pembrolizumab cohort had platinum-sensitive disease. Following ICI treatment, 19 patients were treated with PCE and the remaining 40 with PTX+Cmab. PE-based chemotherapy induced favorable and prompt tumor shrinkage even in cases where ICI was not effective, with a median change in the summed dimensions of target lesions of -43.4%, resulting in an ORR of 62.7%. Median time to response was 1.8 months. The patients in the pembrolizumab cohort appeared to have a numerically higher response rate than those receiving nivolumab (80.0% vs. 56.8%). For the 59 patients, progression-free survival and overall survival, calculated from the initiation of PE-based chemotherapy, were 4.6 months and 17.1 months, respectively. Grade ≥3 adverse events occurred in 40.7%, and no treatment-related death was observed. Conclusion: PE-based chemotherapy following ICI is encouraging for its robust antitumor efficacy in R/M SCCHN. Competing Interests: MT reports grants and personal fees from Ono Pharmaceutical and Bayer; personal fees from MSD, BMS, Merck Biopharma, Pfizer, Rakuten Medical, Lilly, Boehringer Ingelheim, Eisai, Chugai Pharmaceutical, Daiichi-Sankyo, Janssen Pharmaceutical, Genmab, Astra Zeneca, Abbvie and Astellas, outside the submitted work; SO reports personal fees from Ono Pharmaceutical, MSD, BMS, Merck Biopharma; TE reports personal fees from Ono Pharmaceutical, Bayer, MSD, and Merck Biopharma outside the submitted work. YU reports personal fees from BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Tanaka, Enokida, Okano, Fujisawa, Tanaka, Takeshita, Onaga, Hoshi, Wada, Sato, Ueda and Tahara.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu